Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines against Mycobacterium tuberculosis

Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, MD 20892, USA.
Clinical and vaccine Immunology: CVI (Impact Factor: 2.37). 06/2009; 16(7):1025-32. DOI: 10.1128/CVI.00067-09
Source: PubMed

ABSTRACT The development and characterization of new tuberculosis (TB) vaccines has been impeded by the lack of reproducible and reliable in vitro assays for measuring vaccine activity. In this study, we developed a murine in vitro mycobacterial growth inhibition assay for evaluating TB vaccines that directly assesses the capacity of immune splenocytes to control the growth of Mycobacterium tuberculosis within infected macrophages. Using this in vitro assay, protective immune responses induced by immunization with five different types of TB vaccine preparations (Mycobacterium bovis BCG, an attenuated M. tuberculosis mutant strain, a DNA vaccine, a modified vaccinia virus strain Ankara [MVA] construct expressing four TB antigens, and a TB fusion protein formulated in adjuvant) can be detected. Importantly, the levels of vaccine-induced mycobacterial growth-inhibitory responses seen in vitro after 1 week of coculture correlated with the protective immune responses detected in vivo at 28 days postchallenge in a mouse model of pulmonary tuberculosis. In addition, similar patterns of cytokine expression were evoked at day 7 of the in vitro culture by immune splenocytes taken from animals immunized with the different TB vaccines. Among the consistently upregulated cytokines detected in the immune cocultures are gamma interferon, growth differentiation factor 15, interleukin-21 (IL-21), IL-27, and tumor necrosis factor alpha. Overall, we have developed an in vitro functional assay that may be useful for screening and comparing new TB vaccine preparations, investigating vaccine-induced protective mechanisms, and assessing manufacturing issues, including product potency and stability.

Download full-text


Available from: Steven C Derrick, Aug 14, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of every vaccine depends in part on appropriate vaccine handling from the manufacturer to its utilization. There is need for continuous monitoring of vaccine to ensure that cold-chain system is maintained throughout the product lifespan. This study aims to validate the BCG vaccines used in immunization in SouthEast , Nigeria. The potency of the vaccines was determined by viable count on Soybean-Casein-Digest Agarafter incubation of 50µl of 1: 40,000 dilutions of the vaccines at 37°C for 30 days. Ten replicate plates were used and result reported as mean ±SD. The viable counts in the vaccines were compared with the labeled potency on the vials. The immunogenicity test was done by Antibody Induction Method. This involves measuring the neutralizing antibodies in a control group (given physiological saline) and immunized group after 30 days using the enzyme-linked immunosorbent assay (ELISA). Anti-tuberculosis antibodies' concentration was determined by absorbance measurement at 450nm wavelength. Viable counts in the BCG vaccine samples were 54.6±11.79 > 51.91±11.35 > 48.18±15.33 > 44.91±16.29 > 44.55±15.69 CFU/50µl (dilution factor was 40,000). The immunogenicity test shows that the IgG titers for the BCG vaccines from control, Enugu/Ebonyi, Imo, Anambra and Abia were 0.645, 1.567, 1.507, 1.451 and 1.286 respectively while the IgMtitres were 0.689, 0.736, 0.805, 0.792 and 0.715 respectively. One way analysis of variance shows that there is statistical difference in the IgG antibody titer produced by the control compared to the vaccines (P value < 0.0001). The IgG antibody was enough to confer protection. Neither the control nor the vaccines from the states produced enough protective IgM. There is no statistical difference in the IgM antibody titer produced by the control compared to the vaccines (P value = 0.1058). The vaccines were all within their labeled potency and have good immunogenicity profile.
    African journal of pharmacy and pharmacology 01/2015; 8(47):1186-1191. DOI:10.5897/AJPP2014.4198 · 0.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: New vaccines and novel immunization strategies are needed to improve the control of the global tuberculosis epidemic. To facilitate vaccine development, we have been creating in vitro mycobacterial intra-macrophage growth inhibition assays. Here we describe the development of an in vitro assay designed for BSL-2 laboratories which measures the capacity of vaccine-induced immune splenocytes to control the growth of isoniazid-resistant Mycobacterium bovis BCG (INH(r) BCG). The use of the INH(r) BCG as the infecting organism allows the discrimination of BCG bacilli used in murine vaccinations from BCG used in the in vitro assay. In this study, we showed that protective immune responses evoked by four different types of Mycobacterium tuberculosis vaccines [BCG, an ESAT6/Antigen 85B fusion protein formulated in DDA/MPL adjuvant, a DNA vaccine expressing the same fusion protein, and a TB Modified Vaccinia Ankara construct expressing four TB antigens (MVA-4TB)] were detected. Importantly, the levels of vaccine-induced protective immunity seen in the in vitro assay correlated with the results from in vivo protection studies in the mouse model of pulmonary tuberculosis. Furthermore, the growth inhibition data for the INH(r) BCG assay was similar to the previously reported results for a M. tuberculosis infection assay. The cytokine expression profiles at day 7 of the INH(r) BCG growth inhibition studies were also similar but not identical to the cytokine patterns detected in earlier M. tuberculosis co-culture assays. Overall, we have shown that a BSL-2 compatible in vitro growth inhibition assay using INH(r) BCG as the intra-macrophage target organism should be useful in developing and evaluating new TB immunization strategies.
    Vaccine 10/2009; 28(2):317-22. DOI:10.1016/j.vaccine.2009.10.047 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Novel immunization strategies are needed to enhance the global control of tuberculosis (TB). In this study, we assessed the immunizing activity of a recombinant modified vaccinia Ankara (MVA) construct (MVA/IL-15/5Mtb) which overexpresses five Mycobacterium tuberculosis antigens (antigen 85A, antigen 85B, ESAT6, HSP60, and Mtb39), as well as the molecular adjuvant interleukin-15 (IL-15). Homologous prime/boost studies showed that the MVA/IL-15/5Mtb vaccine induced moderate but highly persistent protective immune responses for at least 16 months after the initial vaccination and that the interval between the prime and boost did not significantly alter vaccine-induced antituberculosis protective immunity. At 16 months, when the Mycobacterium bovis BCG and MVA/IL-15/5Mtb vaccine-induced protection was essentially equivalent, the protective responses after a tuberculous challenge were associated with elevated levels of gamma interferon (IFN-gamma), IL-17F, Cxcl9, and Cxcl10. To amplify the immunizing potential of the MVA/IL-15/5Mtb vaccine, a heterologous prime/boost regimen was tested using an ESAT6-antigen 85B (E6-85) fusion protein formulated in dimethyldiotacylammonium bromide/monophosphoryl lipid A (DDA/MPL) adjuvant as the priming vaccine and the MVA/IL-15/5Mtb recombinant virus as the boosting agent. When MVA/IL-15/5Mtb vaccine boosting was done at 2 or 6 months following the final fusion protein injections, the prime/boost regimen evoked protective responses against an aerogenic M. tuberculosis challenge which was equivalent to that induced by BCG immunization. Long-term memory after immunization with the E6-85-MVA/IL-15/5Mtb combination regimen was associated with the induction of monofunctional CD4 and CD8 IFN-gamma-producing T cells and multifunctional CD4 and CD8 T cells expressing IFN-gamma/tumor necrosis factor alpha (TNF-alpha), TNF-alpha/IL-2, and IFN-gamma/TNF-alpha/IL-2. In contrast, BCG-induced protection was characterized by fewer CD4 and CD8 monofunctional T cells expressing IFN-gamma and only IFN-gamma/TNF-alpha and IFN-gamma/TNF-alpha/IL-2 expressing multifunctional T (MFT) cells. Taken together, these results suggest that a heterologous prime/boost protocol using an MVA-based tuberculosis vaccines to boost after priming with TB protein/adjuvant preparations should be considered when designing long-lived TB immunization strategies.
    Clinical and vaccine Immunology: CVI 03/2010; 17(5):793-801. DOI:10.1128/CVI.00006-10 · 2.37 Impact Factor

Similar Publications